Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QCT Sub-Study of Phase III Odanacatib Fracture Trial in Osteoporotic Postmenopausal Women
2009-011920-69Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postmenopausal osteoporosis comparing Odanacatib with Placebo (2 arms). Primary endpoints: Trabecular volumetric bone mineral density (vBMD) of the lumbar spine and hip, Trabecular bone volume of the lumbar spine and hip and 2 more. Started May 2009; status: completed.
02
Drugs
odanacatib
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on 2009-011920-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011920-69.